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Abstract
Background: Neuroblastoma is a pediatric tumor of neural crest cells that is clinically characterized by
its variable evolution, from spontaneous regression to malignancy. Despite many advances in
neuroblastoma research, 60% of neuroblastoma, which are essentially metastatic cases, are associated with
poor clinical outcome due to the lack of effectiveness of current therapeutic strategies. Membrane-type 1
matrix metalloproteinase (MT1-MMP, MMP-14), an enzyme involved in several steps in tumor progression,
has previously been shown to be associated with poor clinical outcome for neuroblastoma. Based on our
recent demonstration that MT1-MMP phosphorylation is involved in the growth of fibrosarcoma tumors,
we examined the potential role of phosphorylated MT1-MMP in neuroblastoma progression.
Methods: Tyrosine phosphorylated MT1-MMP was immunostained on tissue microarray samples from 55
patients with neuroblastoma detected by mass screening (known to be predominantly associated with
favourable outcome), and from 234 patients with standard diagnosed neuroblastoma. In addition, the
effects of a non phosphorylable version of MT1-MMP on neuroblastoma cell migration and proliferation
were investigated within three-dimensional collagen matrices.
Results: Although there is no correlation between the extent of tyrosine phosphorylation of MT1-MMP
(pMT1-MMP) and MYCN amplification or clinical stage, we observed greater phosphorylation of pMT1-
MMP in standard neuroblastoma, while it is less evident in neuroblastoma from mass screening samples (P
= 0.0006) or in neuroblastoma samples from patients younger than one year (P = 0.0002). In vitro
experiments showed that overexpression of a non-phosphorylable version of MT1-MMP reduced MT1-
MMP-mediated neuroblastoma cell migration and proliferation within a three-dimensional type I collagen
matrix, suggesting a role for the phosphorylated enzyme in the invasive properties of neuroblastoma cells.
Conclusion: Overall, these results suggest that tyrosine phosphorylated MT1-MMP plays an important
role in neuroblastoma progression and that its expression is preferentially observed in tumor specimens
from neuroblastoma patients showing poor clinical outcome.
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Neuroblastoma (NB) is the most common extracranial
solid cancer in childhood, accounting for 15% of all can-
cer-related fatalities in children [1]. NB is a neuroendo-
crine malignant tumor of the autonomic nervous system
that arises from neural crest cells [2]. NB shows heteroge-
neous pathological characteristics due to its variable sites
of origin, diverse histopathologic appearance and bio-
logic characteristics. This malignant tumor exhibits a
broad spectrum of clinical features, including spontane-
ous regression without any treatment, maturation to a
benign ganglioneuroma, or progression to metastasis
leading to death. Numerous factors, such as patient's age
at diagnostic, stage of disease, tumor histopathology and
genetic abnormalities have all been shown to influence
NB progression [3]. Among them, the metastatic status
(Stage 4) is a very strong prognosis factor indicating poor
outcome. Survival of children older than one year with an
advanced stage of NB is poor despite aggressive treatment,
as opposed to the survival of children younger than one
year [4]. NB secretes catecholamine metabolites that are
excreted in urine, offering a non-invasive diagnostic tech-
nique. This observation has led to the suggestion of
screening for NB in infants using specific catecholamine
markers. Large studies showed that mass screening did not
appear to reduce neither the disease-related mortality nor
the yearly numbers of aggressive NB [5-7]. Moreover,
patients with mass screening-detected NB very rarely died
from tumor progression [8]. Although the mechanisms
underlying NB progression have been under intense
investigation, therapeutic advances have failed to signifi-
cantly increase the survival rates of children with aggres-
sive NB.
Matrix metalloproteinases (MMPs), a family of zinc-
dependent endopeptidases that degrade extracellular
matrix (ECM) components, play crucial roles in several
processes underlying tumor progression, including cell
attachment, cell migration, invasiveness, cell prolifera-
tion, apoptosis, and angiogenesis [9-12]. There are 23 dif-
ferent human MMPs described to date, some of which are
secreted in the pericellular environment while others are
associated with the cell membrane. Membrane-type 1
matrix metalloproteinase (MT1-MMP, MMP-14), the best
characterized membrane-anchored MMP, plays essential
roles in tumor cell migration and invasion by acting as a
potent matrix-degrading protease that digests a broad
spectrum of ECM proteins [13-15] as well as a number of
cell surface-associated adhesion receptors [16,17]. In par-
ticular, elegant studies have unequivocally shown that
MT1-MMP-mediated pericellular proteolysis of the ECM
is essential for tissue-invasive activity of tumor cells [18]
as well as for tumor cell growth in an otherwise growth-
restrictive three-dimensional (3-D) environment [19].
Accordingly, MT1-MMP is overexpressed in many types of
tumors, including breast, colon, head and neck [20], cer-
vical [21], gastric [22] and lung [23] carcinomas, as well as
in brain tumors [24]. Moreover, MT1-MMP expression
has been shown to correlate with unfavourable outcome
in pediatric NB patients [25].
In addition to its important matrix-degrading activity,
MT1-MMP contains a short cytoplasmic sequence that is
involved in regulation of the enzyme activity [26] as well
as in the activation of signal transduction processes
[27,28]. Previous work from our laboratory has also
shown that MT1-MMP is phosphorylated on its unique
cytoplasmic tyrosine residue and that this phosphoryla-
tion also participates in tumor cell migration and invasion
[29,30]. We have also shown that impaired tyrosine phos-
phorylation of MT1-MMP markedly reduced the tumori-
genic properties of the highly invasive HT-1080
fibrosarcoma, leading to a complete inhibition of tumor
growth in nude mice [31].
The aim of the present study is to investigate the role of
tyrosine phosphorylated MT1-MMP (pMT1-MMP) in NB
progression and its relation to clinical outcome. We report
herein that tyrosine phosphorylation of the enzyme plays
an important role in NB cell migration and proliferation
within 3D collagen matrix in vitro. Furthermore, expres-
sion of pMT1-MMP correlated with some clinical features,
patient age at diagnosis and mass screening versus stand-




The study protocol have been performed with the
approval of the CHU Sainte-Justine Ethic Committee of
Research (protocol 2244), in accordance with the Hel-
sinki Declaration. All tumor samples used in this study
were obtained at diagnosis. Tumor samples from mass
screening for NB were collected from 55 patients in two
different countries: 35 came from Québec (Canada) and
20 from Otsu (Japan, [32]) (Table 1). Tumors were diag-
nosed between August 1989 and April 2002 with a
median follow-up of 170 months. Among these 55
patients, there were 26 girls and 29 boys with a median
age of 7 months. Three patients were older than one year
at diagnosis and one tumor had MYCN amplification.
According to the International Neuroblastoma Staging
System classification [33], there were 16 patients in stage
1, 15 in stage 2, 9 in stage 3, 6 in stage 4 and 9 in stage 4S.
One patient died from NB. Tumors samples from stand-
ard NB came from 234 patients with NB who were treated
and followed in four centers: Bicêtre hospital (Le Kremlin-
Bicêtre, France), Gustave Roussy Institute (Villejuif,
France), the American Hospital (Reims, France) and CHU
Sainte-Justine (Montréal, Canada). These patients were
diagnosed between July 1988 and March 2008, with a
median follow-up of 58.5 months. 167 patients were stillPage 2 of 9
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girls, with a median age of 25 months. Seventy three
patients were under one year of age and 40 were older
than 5 at the time of diagnosis (Table 1). There were 52
patients in stage 1, 32 in stage 2, 35 in stage 3, 97 in stage
4 and 18 in stage 4S. The global survival at the end of the
follow-up was 91.7% in patients under one year, 65.2% in
patient of one to five years and 52.5% in those of more
than five years. Stage-related global survival (according to
Kaplan-Meier method) was 94.2% in stage 1, 100% in
stage 2, 85.7% in stage 3, 42.2% in stage 4 and 83.3% in
stage 4S (Table 1).
Tissue Microarray (TMA) construction
On average, 4 tissue cylinders of 0.6 mm diameter were
obtained and were transferred into a recipient paraffin
block using a manual tissue arrayer (Alphelys, Plaisir,
France). Mass screening NB samples consisted of 55 pri-
mary tumors and 21 metastases (15 lymph nodes and 6
hepatic metastases). TMA blocks of standard NB con-
tained 234 primary tumors and 78 metastases (68 lymph
nodes, 8 hepatic and 2 cutaneous metastases) and 56
paired control normal tissues (40 adrenal glands and 16
sympathetic ganglia).
Immunohistochemistry
Five-μm sections of TMA blocks were cut and deparaffin-
ized, treated with 1% H2O2 and submitted to antigen
retrieval by microwave oven treatment for 15 min in cit-
rate buffer. Immunohistochemical staining was per-
formed on these sections using pMT1-MMP polyclonal
antibodies (1/100, 1 hour at room temperature [29,31]).
Samples were then incubated with biotinylated immu-
noglobulin (LSAB II, DAKO, Glostrup, Denmark) at room
temperature for 30 min followed by avidin-biotin peroxi-
dase complexes for 30 min. Rabbit IgG was used as a neg-
ative control. Three-amino-9-ethylcarbazol was used as
the chromogen and haematoxylin as the nuclear counter-
stain. TMA sections were treated in one set of immunos-
taining. Two pathologists, blinded from clinical data,
independently evaluated immunostaining under a light
microscope at a magnification of 400×. Immunostaining
scores were established by a semi-quantitative optical
analysis of samples containing more than 10 neuroblasts
assessing the percentage of positive cells in each sample: 0
= all cells negative, 1+ = 1 to 25% of positive cells, 2+ = 26
to 50% of positive cells, 3+ = 51 to 75% of positive cells
and 4+ more than 76% of positive cells. Inter-observer
agreement was calculated by the kappa coefficient. The
observed agreement between the two pathologists was
Kappa = 0.61, 95% CI = [0.58-0.64], P < 0.0001.
Statistical analysis
The univariate relationship between immunohistochemi-
cal expression of pMT1-MMP and biological and clinical
data (standard and mass screening NB, control samples,
primary tumors, metastasis, stage 1 and stage 4 and
patient under one year, MYCN amplification) was investi-
gated by Student's t-test. Kaplan-Meier analysis was used
to estimate cancer-specific survival and the groups were
compared with the log-rank test. All analyses were per-
formed with Graphpad Prism software. P < 0.05 was con-
sidered statistically significant.
Table 1: Clinical features of 289 patients with NB diagnosis
Mass screening Standard
Characteristics Number (%) Survival (%) Numbers (%) Survival (%)
Total 55 (100) 98 234 (100) 71.3
Gender
Female 26 (47.3) 114 (48.7)
Male 29 (52.7) 120 (51.3)
Age
Median (range) in months 30 (0-151) 25 (0-183)
< 1 year 52 (94.5) 98 73 (31.2) 91.7
1-5 years 3 (5.5) 100 121 (51.8) 65.2
> 5 years 40 (17) 52.5
Clinical stage
1 16 (29.1) 100 52 (22.2) 94.2
2 15 (27.2) 93 32 (13.7) 100
3 9 (16.4) 100 35 (15) 85.7
4 6 (10.9) 100 97 (41.4) 42.2
4S 9 (16.4) 100 18 (7.7) 83.3
MYCN oncogene
< 10 copies 54 (98.2) 100 160 (82.9) 79.6
> 10 copies 1 (1.8) 0 33 (18.1) 53.1Page 3 of 9
(page number not for citation purposes)
BMC Cancer 2009, 9:422 http://www.biomedcentral.com/1471-2407/9/422Cell lines and transfection
NB-10 cells were from St Jude Children's Research Hospi-
tal (Memphis, TN, USA) and were a gift from Dr. Daniel
Sinnett (CHU Sainte-Justine, Montreal). SK-N-SH cells
were obtained from the American Type Culture Collec-
tion. Cells were cultured at 37°C in a humidified atmos-
phere composed of 95% air and 5% CO2 and were grown
in Eagle's minimum essential medium (EMEM) supple-
mented with 1 mM sodium pyruvate and 10% fetal
bovine serum (FBS). The cDNAs encoding the full-length
human MT1-MMP (MT1 WT) and its cytoplasmic mutant
(MT1 Y573F) have been previously described [29]. NB-10
and SK-N-SH neuroblastoma cells were transiently trans-
fected using the FuGENE HD transfection reagent (Roche
Applied Science) according to the manufacturer's instruc-
tions.
Western Blotting
The procedures used were described previously [34].
Briefly, equal amounts of protein from cell lysates were
solubilized in Laemmli sample buffer, boiled for 5 min,
separated by SDS-PAGE, transferred onto PVDF mem-
branes and immunodetected with antibodies against
MT1-MMP (MAB3328, Chemicon International) or
GAPDH (Santa Cruz Biothechnology, CA, USA). For
phosphorylated MT1-MMP assessment, cell lysates were
immunoprecipitated with MT1-MMP antibodies
(MAB3328) prior to Western blot procedure and immun-
odetection with pMT1-MMP polyclonal antibodies [29].
Cell Migration Assay
Migration assays were performed on transwells pre-coated
with 10 μg/ml type I collagen. Transwells were assembled
into 24-well plates and the lower chambers were filled
with EMEM containing 10% FBS. Transfected cells were
harvested, resuspended in 100 μl of fresh serum-free
EMEM at a density of 5 × 105 cells/ml, and inoculated into
the upper chamber of each transwell. The plates were then
placed at 37°C in 5% CO2, 95% air for 3 h, and cells that
had migrated were quantified using computer-assisted
imaging (Northern Eclipse 6.0; Empix Imaging, Missis-
sauga, ON, Canada). Statistical analyses were performed
by one-way analysis of variance (ANOVA) followed by
Bonferroni post-tests using GraphPad Prism software. P <
0.05 was considered statistically significant.
3D cell proliferation
Type I collagen was extracted from rat tail and resus-
pended at 2.7 mg/ml in acetic acid. Cells were mixed with
10× EMEM, 0.17N NaOH and 2.7 mg/ml type I collagen.
The mixture was allowed to gel for 45 min at 37°C and
EMEM containing 10% FBS was added atop. Collagen gels
were dissolved with 2 mg/ml bacterial collagenase
(Sigma, Burlington, ON, Canada) and viable cells were
counted by trypan blue exclusion using a hemacytometer.
Statistical analyses were performed by one-way ANOVA
followed by Bonferroni post-tests using GraphPad Prism
software. P < 0.05 was considered statistically significant.
Fluorescence and Confocal Microscopy
NB-10 cells were seeded on 10 μg/ml type I collagen-
coated cover-slips, serum-starved overnight and stimu-
lated with serum for 15 min. Cells were then fixed with
3.7% formaldehyde for 15 min, incubated for 5 min with
20 μM Hoechst (Sigma) for nuclei staining, permeabilized
with 0.2% Triton X-100 for 5 min and blocked (1% BSA
in Tris Buffered Saline containing 0.1% Tween 20) for 30
min. Samples were then incubated with FITC-conjugated
phalloidin (for actin staining) for 30 min, and stained
with specific primary antibodies against pMT1-MMP [29]
for 30 min, followed by a 30 minute incubation with
rhodamine-conjugated secondary antibodies (Molecular
Probes - Invitrogen, Burlington, ON, Canada). Samples
were covered with Immuno-Fluor Mounting Medium
Immunostaining of pMT1-MMP in NB samplesFigure 1
Immunostaining of pMT1-MMP in NB samples. pMT1-
MMP was immunostained in a tissue microarray of NB speci-
mens.Page 4 of 9
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ualized and photographed using a Zeiss LSM 510 Meta
confocal microscope.
Results and Discussion
Phosphorylation of MT1-MMP in NB specimens
NB is characterized by its variable evolution that allows
separation of these tumors into two major groups.
Tumors in the first group are relatively benign, localized,
well-differentiated and are successfully treated by surgery
alone, or they sometimes regress spontaneously. Tumors
in the second group (60% of all NB) are invasive and met-
astatic, and are usually associated with poor clinical out-
come in spite of intensive treatment [35]. Tumors
detected by mass screening are usually part of the first
group and are associated with good clinical outcome.
Notwithstanding many advances in the identification of
the molecular factors associated with the poor clinical
income of NB, including amplified expression of the
MYCN oncogene, deletion of 1p or 11q [36], lack of
CD44 expression [37] as well as expression of neuro-
trophin receptors [2], the molecular mechanisms respon-
sible for the progression/regression evolution of NB are
poorly understood.
Since a previous study showed correlation between MT1-
MMP expression and advanced stage of NB and patients
survival [25], we examined in this study whether phos-
phorylation of MT1-MMP was involved in NB progres-
sion. 289 NB samples (Table 1) were immunostained
with pMT1-MMP antibodies [29,31]. The phosphorylated
MT1-MMP was membranous and cytoplasmic and was
only found in neuroblastic cells (Figure 1). As shown in
Figure 1, normal control samples presented a poor and
infrequent phosphorylation of MT1-MMP (33.9% of sam-
ple, means intensity 0.34), NB had a moderate and fre-
quent phosphorylation of MT1-MMP (64.7% of sample,
means intensity 0.72) similar to those of metastases
(73.8% of sample, means intensity 0.72)
Relationship between pMT1-MMP and clinicopathologic 
parameters
We next evaluated the correlation between pMT1-MMP
immunostaining and clinicopathologic features (Table 2).
Analysis of immunostaining showed that MT1-MMP
exhibits greater phosphorylation in NB specimens com-
pared to control samples (P < 0.0001). More precisely,
immunostaining of pMT1-MMP was observed in 187 of
289 (64.7%) of NB specimens, while only 19 of 56
(33.9%) of normal specimens were positive for MT1-
MMP. pMT1-MMP detection was significantly lower in
mass screening NB (24 of 55 (43.6%)) than in standard
NB (160 of 234 (68.4%), P = 0.0006). Moreover, pMT1-
MMP detection was higher in patients older than 1 year
than in those under one year (P = 0.0002). However, no
significant relationship was observed between pMT1-
MMP and the tumor site (primary versus metastasis, P =
0.5900), clinical stage (stage 1 versus stage 4, P = 0.3700)
or MYCN amplification (amplified versus no amplified P
= 0.1000).
A non phosphorylable mutant of MT1-MMP inhibits MT1-
MMP-mediated tumorigenic properties of NB in vitro
We have previously shown that tyrosine phosphorylation
of MT1-MMP, in addition to affecting its proteolytic activ-
ity, plays a critical role in the tumorigenicity of fibrosar-
coma cells [29,31]. To determine the role of
phosphorylated MT1-MMP in NB in vitro, NB-10 and SK-
Table 2: Univariate analysis of pMT1-MMP expression in clinicopathologic features






Normal control samples 56 0.34 19 (33.9) 37 (66.1)
Tumor from primary site 289 0.72 187 (64.7) 102 (35.3) 0.0001
Tumor from metastasis 103 0.72 76 (73.8) 27 (26.2) 0.5900
Age
< 1 year 125 0.64 58 (46.4) 67 (53.6) 0.0002
> 1 year 184 0.78 124 (67.4) 60 (32.6)
Clinical stage
1 68 0.66 41 (60.3) 27 (39.7) 0.3700
4 103 0.75 69 (67.0) 34 (33.0)
Specimen type
Mass screening 55 0.31 24 (43.6) 31 (56.4) 0.0006
Standard 234 0.8 160 (68.4) 74 (31.6)
MYCN oncogene
Amplified 34 0.52 21 (61.8) 13 (38.2) 0.1000
Not amplified 214 0.69 100 (46.7) 114 (53.3)
*N: number of specimensPage 5 of 9
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Inhibition of neuroblastoma cell proliferation and invasion by a non-phosphorylable mutant of MT1-MMPFigure 2
Inhibition of neuroblastoma cell proliferation and invasion by a non-phosphorylable mutant of MT1-MMP. NB-
10 and SK-N-SH neuroblastoma cells were transfected with either pcDNA, WT or Y573F forms of MT1-MMP. 24 h post-
transfection, cells were harvested and transfection efficiency as well as MT1-MMP phosphorylation levels were determined by 
Western blot (A); IP: immunoprecipitation, ID: immunodection, H: immunoglobulin heavy chain. (B) 5 × 104 transfected cells 
were subjected to migration assays, using Transwells pre-coated with 10 μg/ml type I collagen and 10% serum as chemoattract-
ant. (C) 2 × 104 transfected cells were embedded within type I collagen gels and allowed to grow during 5 days. Data are means 
± SEM. *P < 0.05; **P < 0.01; ***P < 0.001.
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Localization of tyrosine phosphorylated MT1-MMP in NB cellsFigure 3
Localization of tyrosine phosphorylated MT1-MMP in NB cells. NB-10 neuroblastoma cells were transfected with 
either pcDNA, WT or Y573F forms of MT1-MMP. 24 h post-transfection, cells were seeded on 10 μg/ml type I collagen-
coated cover slips, serum-starved for 18 h, stimulated for 15 min with serum and fixed with formaldehyde. Nuclei, actin and 
pMT1-MMP were stained as described in Material and Methods. Images were acquired using a Zeiss LSM 510 Meta confocal 
microscope. The white scale bar represents 50 μm.
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wild type (WT) or the non phosphorylable version
(Y573F) of MT1-MMP. As shown in Figure 2A, due to ele-
vated basal expression of MT1-MMP in SK-N-SH cells,
overexpression of WT MT1-MMP in these cells had a rela-
tively low stimulatory effect on cell migration while the
Y573F mutant strongly diminished both cell migration
and MT1-MMP phosphorylation (Figure 2A-B). However,
in the NB-10 cells which express low basal levels of MT1-
MMP, overexpression of WT MT1-MMP markedly
increased cell migration (3-fold), this effect being com-
pletely abolished by overexpression of the Y573F mutant
(Figure 2B). These results are in agreement with previous
findings showing the dominant-negative properties of the
non phosphorylable mutant of MT1-MMP [29,31].
We next evaluated the impact of MT1-MMP phosphoryla-
tion on NB proliferation within 3D collagen matrices. As
shown in Figure 2C, overexpression of the wild type ver-
sion of the enzyme induced a marked increase in the pro-
liferation of both SK-N-SH and NB-10 cells within 3D
collagen matrices, this stimulatory effect being abolished
by the non phosphorylable MT1-MMP mutant. Previous
study from our laboratory demonstrated that the inhibi-
tory effect of the Y573F dominant-negative mutant of
MT1-MMP on tumor cell proliferation is not related to
defective proteolysis, since this mutant retained the ability
to activate proMMP-2 and to degrade type I collagen [31].
The inhibitory effect of the Y573F mutant on NB cell
migration and proliferation correlated with a decrease in
the levels of phosphorylated MT1-MMP (Figure 3). More-
over, serum-induced relocalization of tyrosine phosphor-
ylated MT1-MMP to peripheral actin-rich structures, a
process important for cell migration, was completely
abolished by overexpression of the non-phosphorylable
mutant of MT1-MMP (Figure 3, [30]).
These results suggest that phosphorylated MT1-MMP may
play an important role in the MT1-MMP-mediated pro-
migratory and pro-invasive properties of NB in vitro.
Conclusion
Overall, the findings reported in this study show that
reduction of the tyrosine phosphorylation of MT1-MMP
reduced the MT1-MMP-mediated tumorigenic properties
of NB cells in vitro, and that pMT1-MMP is preferentially
expressed in tumor specimens from standard NB and in
patients older than one year, two clinical features associ-
ated with poor outcome in NB patients. In addition, our
previous findings suggest that phosphorylation of MT1-
MMP is observed under tumorigenic rather than normal
conditions [31]. Therefore, phosphorylation of MT1-
MMP could represent the ''molecular switch" in NB cells
responsible for the evolution from benign to malignant
tumor. The identification of pMT1-MMP as an important
player in the process of NB progression could be useful for
the development of new therapeutic strategies for NB
patients who cannot be cured with current therapeutic
approaches.
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